PCM
ARQT icon

Peregrine Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Peregrine Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.64M Sell
291,447
-14,825
-5% -$345K 0.25% 130
2026
Q1 		$7.22M Buy
+306,272
New +$7.82M 0.27% 112

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Peregrine Capital Management's ARQT Position: Q2 2026 in Review

Peregrine Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 4.8% in Q2 2026, selling an estimated $345K and leaving 291,447 shares worth $7.64M. The position accounts for 0.25% of the portfolio, ranked #130.

Peregrine Capital Management first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Peregrine Capital Management held 291,447 shares of Arcutis Biotherapeutics worth $7.64M as of Q2 2026.
  • Peregrine Capital Management sold 14,825 Arcutis Biotherapeutics shares in Q2 2026, an estimated $345K.
  • Arcutis Biotherapeutics made up 0.25% of Peregrine Capital Management's portfolio in Q2 2026, its #130 holding.
  • Peregrine Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.